ENTRADA THERAPEUTICS INC (TRDA) Stock Analyst Ratings
USA - NASDAQ:TRDA - US29384C1080 - Common Stock
8.82 USD
+0.35 (+4.13%)
8.75 USD
-0.07 (-0.79%)
ChartMill assigns a Buy % Consensus number of 84% to TRDA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 18.87. This target is 113.95% above the current price.
TRDA was analyzed by 10 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about TRDA.
In the previous month the buy percentage consensus was at a similar level.
TRDA was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-05-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-05 | Roth MKM | Initiate | Buy |
| 2024-11-06 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-11-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-26 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-01-05 | Oppenheimer | Initiate | Outperform |
| 2023-11-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-04-03 | HC Wainwright & Co. | Initiate | Buy |
| 2022-11-08 | Goldman Sachs | Maintains | Neutral |
| 2022-08-16 | Goldman Sachs | Maintains | Neutral |
| 2022-05-24 | Goldman Sachs | Maintains | Neutral |
| 2021-11-24 | Evercore ISI Group | Initiate | Outperform |
| 2021-11-23 | Cowen & Co. | Initiate | Outperform |
| 2021-11-23 | Goldman Sachs | Initiate | Neutral |
ENTRADA THERAPEUTICS INC / TRDA FAQ
What do analysts expect the price target to be for ENTRADA THERAPEUTICS INC (TRDA)?
10 analysts have analysed TRDA and the average price target is 18.87 USD. This implies a price increase of 113.95% is expected in the next year compared to the current price of 8.82.
What is the consensus rating for ENTRADA THERAPEUTICS INC (TRDA) stock?
The consensus rating for ENTRADA THERAPEUTICS INC (TRDA) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for TRDA stock?
The number of analysts covering ENTRADA THERAPEUTICS INC (TRDA) is 10.